Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Zhao, X ^a,b   Fu, J ^b,c   Xu, A ^b   Yu, L ^b,c   Zhu, J ^b   Dai, R ^b   Su, B ^b   Luo, T ^b   Li, N ^b   Qin, W ^b   Wang, B ^b   Jiang, J ^b   Li, S ^d   Chen, Y ^b,c   Wang, H ^a,b,c,e  

^a NANJING UNIVERSITY   (China)

^b Eastern Hepatobiliary Surgery Institute/Hospital   (China)

^c National Innovation Alliance for Hepatitis and Liver Cancer   (China)

^d TSINGHUA UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA SMOOTH MUSCLE ACTIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CASPASE 3; COLLAGEN TYPE 1; CYCLINE; CYTOCHROME C; DESMIN; EHOP 016; GANKYRIN; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEASOME; PSMD10 PROTEIN, HUMAN; RAC1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CELL CYCLE; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MALIGNANT TRANSFORMATION; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; WILD TYPE; ANIMAL; CHRONIC DISEASE; GENETICS; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; RAC1 GTP-BINDING PROTEIN;

EID: 84970928401     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.120     Document Type: Article

References (47)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
4. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-436.
5. Park TJ, Kim HS, Byun KH, Jang JJ, Lee YS, Lim IK. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16 (INK4A) exon 1 in hepatocellular carcinoma. Mol Carcinog 2001;30:138-150.
6. Fu X, Tan L, Liu S, Li H, Chen L, Qin J et al. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics. J Cancer Res Clin Oncol 2004;130:514-520.
7. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo H et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005;8:75-87.
8. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000;6:96-99.
9. Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren YB et al. p28 (GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. Gastroenterology 2012;142:1547-1558.e14.
10. Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong LW et al. Oncoprotein p28 GANK binds to RelA and retains NF-kappaB in the cytoplasm through nuclear export. Cell Res 2007;17:1020-1029.
11. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011;53:181-192.
12. Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatology 2011;54:1259-1272.
13. Sun W. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of hepatocytes and hepatoma cells. Hepatology 2011;54:1259-1272.
14. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008;118:3943-3953.
15. Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011;25:634-645.
16. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006;290:G583-G589.
17. Subauste MC, Von Herrath M, Benard V, Chamberlain CE, Chuang TH, Chu K et al. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J Biol Chem 2000;275:9725-9733.
18. Chuang TH, Hahn KM, Lee JD, Danley DE, Bokoch GM. The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes. Mol Biol Cell 1997;8:1687-1698.
19. Jin S, Ray RM, Johnson LR. Rac1 mediates intestinal epithelial cell apoptosis via JNK. Am J Physiol Gastrointest Liver Physiol 2006;291:G1137-G1147.
20. Jin S, Ray RM, Johnson LR. TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 2008;294:G928-G937.
21. Cho Y, Huh KH, Park YJ, Do JH, Joo DJ, Kim MS et al. Cellular function of RhoGDI-alpha mediates the cycling of Rac1 and the regulation of pancreatic beta cell death. Transplant Proc 2012;44:1083-1085.
22. Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai ZF et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene 2013;32:3452-3460.
23. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008;135:510-523.
24. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-635.
25. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NYAcad Sci 2002;963:13-20.
26. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 2014;346:17-23.
27. Liu Y, Higashitsuji H, Itoh K, Sakurai T, Koike K, Hirota K et al. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1. Biochem Biophys Res Commun 2013;432:22-27.
28. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
29. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013;7:275-288.
30. Sun B, Karin M. The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci 2014;35:349-357.
31. McCay PB, Lai EK, Poyer JL, DuBose CM, Janzen EG. Oxygen- and carbon-centered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals in vivo and in vitro. J Biol Chem 1984;259:2135-2143.
32. Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010;30:87-98.
33. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-879.
34. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997;1333:F85-F104.
35. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010;138:347-359.
36. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005;15:36-42.
37. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007;19:142-149.
38. Hochedlinger K, Wagner EF, Sabapathy K. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene 2002;21:2441-2445.
39. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
40. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2013;2:367-383.
41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
42. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-314.
43. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004;3:349-380.
44. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010;52:1322-1333.
45. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-516.
46. Sun H, Chen L, Zhou W, Hu L, Li L, Tu Q et al. The protective role of hydrogen-rich saline in experimental liver injury in mice. J Hepatol 2011;54:471-480.
47. Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H et al. p53 promotes inflammationassociated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013;59:762-768.